Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.
Primary Purpose
Asthma
Status
Completed
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
LAS100977 0.313 μg
LAS100977 0.625 μg
LAS100977 1.25 μg
LAS100977 2.5 μg
Salbutamol 400 μg
Salbutamol placebo
LAS100977 placebo
Sponsored by

About this trial
This is an interventional treatment trial for Asthma focused on measuring COPD
Eligibility Criteria
Inclusion Criteria:
- Adult male and female patients aged 18-70 years (both included).
- Clinical diagnosis of persistent asthma (according to GINA guidelines 2009 update) for at least 6 months prior to screening.
- Screening FEV1 value of 60% < FEV1 ≤ 85% of the predicted normal value.
- FEV1 reversibility ≥ 12% and an absolute increase of at least 200 ml over baseline value after inhalation of 400µg (four inhalations) of salbutamol.
- Pre-dose FEV1 value of first treatment period within the range of ± 20% of the FEV1 measured at screening prior to salbutamol inhalation.
- Patients on a stable dose and regimen
Exclusion Criteria:
- Current smokers, former smokers within the last 6 months, or ex-smokers with a history of more than 10 pack-years.
- Patients diagnosed with COPD.
- Recent Respiratory tract infections within 6 weeks before Screening Visit.
- Intubation (ever) or hospitalization for longer than 24 hours for the management of an asthma exacerbation within the preceding 6 weeks of the screening visit.
- Clinically significant respiratory conditions.
- Clinically significant cardiovascular conditions.
- Patients unable to properly use a dry powder or pMDI inhaler device or unable to perform acceptable spirometry.
- Clinically relevant abnormalities laboratory, ECG parameters or physical examination results at the screening evaluation that in the investigator's opinion, preclude study participation.
- Patients who intend to use any concomitant medication not permitted by this protocol or who have not undergone the required washout period for a particular prohibited medication.
Sites / Locations
- Almirall Investigational Sites#6
- Almirall Investigational Sites#4
- Almirall Investigational Sites#1
- Almirall Investigational Sites#3
- Almirall Investigational Sites#2
- Almirall Investigational Sites#8
- Almirall Investigational Sites#5
- Almirall Investigational Sites#2
- Almirall Investigational Sites#1
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm Type
Experimental
Experimental
Experimental
Active Comparator
Placebo Comparator
Experimental
Arm Label
LAS100977 0.625 μg
LAS100977 1.25 μg
LAS100977 2.5 μg
Salbutamol
Placebo
LAS100977 0.313 μg
Arm Description
Single-dose LAS100977 0.625 μg, during double-blind treatment period
Single-dose LAS100977 1.25 μg, during double-blind treatment period
Single-dose LAS100977 2.5 μg, during double-blind treatment period
Single-dose salbutamol 400 μg, during double-blind treatment period
Placebo to LAS100977, and placebo to salbutamol
Single-dose LAS100977 0.313 μg, during double-blind treatment period
Outcomes
Primary Outcome Measures
Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.
Secondary Outcome Measures
Percentage Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.
Peak Forced Expiratory Volume in One Second (FEV1)
The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.
Time to Peak Forced Expiratory Volume in One Second (FEV1)
The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.
Change From Baseline to Trough Forced Expiratory Volume in One Second (FEV1)
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.
Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-24h at Day 1
FEV1 was normalized to baseline. Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.
Absolute Values of Forced Expiratory Volume (FEV1) at Each Timepoint
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.
Change From Baseline in Forced Expiratory Volume (FEV1) at Each Timepoint
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.
Percentage Change From Baseline in Forced Expiratory Volume (FEV1) at Each Timepoint
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.
Change From Baseline in Peak Forced Vital Capacity (FVC)
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.
Peak Forced Vital Capacity (FVC)
The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.
Time to Peak Forced Vital Capacity (FVC)
The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.
Change From Baseline to Trough Forced Vital Capacity (FVC)
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.
Change From Baseline in Normalized Forced Vital Capacity (FVC) Area Under the Curve (AUC)
FVC was normalized to baseline. Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.
Absolute Values of Forced Vital Capacity (FVC) at Each Timepoint
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.
Change From Baseline in Forced Vital Capacity (FVC) at Each Timepoint
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01425801
Brief Title
Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.
Official Title
A Phase IIa, Randomised, Single Dose, Double-blind, Double-dummy, 6 Way Complete Cross-over, Placebo Controlled Clinical Trial to Assess the Efficacy, Safety and Tolerability of 4 Doses of LAS100977 QD Compared to Placebo and an Active Comparator in Patients With Persistent Asthma.
Study Type
Interventional
2. Study Status
Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
August 1, 2011 (Actual)
Primary Completion Date
February 1, 2012 (Actual)
Study Completion Date
February 1, 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to evaluate the pharmacodynamics of single doses of inhaled LAS100977 QD in patients with persistent asthma.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
COPD
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
62 (Actual)
8. Arms, Groups, and Interventions
Arm Title
LAS100977 0.625 μg
Arm Type
Experimental
Arm Description
Single-dose LAS100977 0.625 μg, during double-blind treatment period
Arm Title
LAS100977 1.25 μg
Arm Type
Experimental
Arm Description
Single-dose LAS100977 1.25 μg, during double-blind treatment period
Arm Title
LAS100977 2.5 μg
Arm Type
Experimental
Arm Description
Single-dose LAS100977 2.5 μg, during double-blind treatment period
Arm Title
Salbutamol
Arm Type
Active Comparator
Arm Description
Single-dose salbutamol 400 μg, during double-blind treatment period
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo to LAS100977, and placebo to salbutamol
Arm Title
LAS100977 0.313 μg
Arm Type
Experimental
Arm Description
Single-dose LAS100977 0.313 μg, during double-blind treatment period
Intervention Type
Drug
Intervention Name(s)
LAS100977 0.313 μg
Intervention Description
Dry powder inhalation, once-daily, single-dose
Intervention Type
Drug
Intervention Name(s)
LAS100977 0.625 μg
Intervention Description
Dry powder inhalation, once-daily, single-dose
Intervention Type
Drug
Intervention Name(s)
LAS100977 1.25 μg
Intervention Description
Dry powder inhalation, once-daily, single-dose
Intervention Type
Drug
Intervention Name(s)
LAS100977 2.5 μg
Intervention Description
Dry powder inhalation, once-daily, single-dose
Intervention Type
Drug
Intervention Name(s)
Salbutamol 400 μg
Intervention Description
Pressurized inhalation suspension, once-daily, single-dose
Intervention Type
Drug
Intervention Name(s)
Salbutamol placebo
Intervention Description
Pressurized inhalation, once-daily
Intervention Type
Drug
Intervention Name(s)
LAS100977 placebo
Intervention Description
Dry powder inhalation, once-daily
Primary Outcome Measure Information:
Title
Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)
Description
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.
Time Frame
Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose
Secondary Outcome Measure Information:
Title
Percentage Change From Baseline in Peak Forced Expiratory Volume in One Second (FEV1)
Description
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.
Time Frame
Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose
Title
Peak Forced Expiratory Volume in One Second (FEV1)
Description
The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.
Time Frame
+15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose
Title
Time to Peak Forced Expiratory Volume in One Second (FEV1)
Description
The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 were selected.
Time Frame
+15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose
Title
Change From Baseline to Trough Forced Expiratory Volume in One Second (FEV1)
Description
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.
Time Frame
Baseline and +23 h and +24 h post-dose
Title
Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) 0-24h at Day 1
Description
FEV1 was normalized to baseline. Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.
Time Frame
Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h and +24 h
Title
Absolute Values of Forced Expiratory Volume (FEV1) at Each Timepoint
Description
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.
Time Frame
Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h
Title
Change From Baseline in Forced Expiratory Volume (FEV1) at Each Timepoint
Description
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.
Time Frame
Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h
Title
Percentage Change From Baseline in Forced Expiratory Volume (FEV1) at Each Timepoint
Description
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.
Time Frame
Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h
Title
Change From Baseline in Peak Forced Vital Capacity (FVC)
Description
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.
Time Frame
Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h post-dose
Title
Peak Forced Vital Capacity (FVC)
Description
The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.
Time Frame
+15 min, +30 min, +1 h, +2 h, +3 h, +4 h
Title
Time to Peak Forced Vital Capacity (FVC)
Description
The peak was computed as the highest value observed for each patient during the 4-hour period immediately after the investigational medicinal product administered in the morning. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.
Time Frame
+15 min, +30 min, +1 h, +2 h, +3 h, +4 h
Title
Change From Baseline to Trough Forced Vital Capacity (FVC)
Description
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). Trough at Day 2 was computed as the average of the two values measured at 23 and 24 hours after administration of the morning dose of investigational medicinal product on Day 1. At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.
Time Frame
Baseline and +23 h +24 h post-dose
Title
Change From Baseline in Normalized Forced Vital Capacity (FVC) Area Under the Curve (AUC)
Description
FVC was normalized to baseline. Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected.
Time Frame
Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h and +24 h
Title
Absolute Values of Forced Vital Capacity (FVC) at Each Timepoint
Description
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.
Time Frame
Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h
Title
Change From Baseline in Forced Vital Capacity (FVC) at Each Timepoint
Description
Baseline was the average of the two values measured just prior to the administration of the dose of investigational medicinal product at Day 1 of each visit (time points -45 min and -15 min). At each time point, three technically adequate lung function measurements were performed by spirometry according to the acceptability and repeatability criteria of the ATS/ERS; the highest values for the FEV1 and FVC were selected. The number of participants analyzed differed between timepoints - the number of participants analyzed at 0.25 h is shown.
Time Frame
Baseline and +15 min, +30 min, +1 h, +2 h, +3 h, +4 h, +6 h, +8 h, +12 h, +14 h, +23 h, +24 h, and +36 h
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adult male and female patients aged 18-70 years (both included).
Clinical diagnosis of persistent asthma (according to GINA guidelines 2009 update) for at least 6 months prior to screening.
Screening FEV1 value of 60% < FEV1 ≤ 85% of the predicted normal value.
FEV1 reversibility ≥ 12% and an absolute increase of at least 200 ml over baseline value after inhalation of 400µg (four inhalations) of salbutamol.
Pre-dose FEV1 value of first treatment period within the range of ± 20% of the FEV1 measured at screening prior to salbutamol inhalation.
Patients on a stable dose and regimen
Exclusion Criteria:
Current smokers, former smokers within the last 6 months, or ex-smokers with a history of more than 10 pack-years.
Patients diagnosed with COPD.
Recent Respiratory tract infections within 6 weeks before Screening Visit.
Intubation (ever) or hospitalization for longer than 24 hours for the management of an asthma exacerbation within the preceding 6 weeks of the screening visit.
Clinically significant respiratory conditions.
Clinically significant cardiovascular conditions.
Patients unable to properly use a dry powder or pMDI inhaler device or unable to perform acceptable spirometry.
Clinically relevant abnormalities laboratory, ECG parameters or physical examination results at the screening evaluation that in the investigator's opinion, preclude study participation.
Patients who intend to use any concomitant medication not permitted by this protocol or who have not undergone the required washout period for a particular prohibited medication.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Carol Astbury, PhD
Organizational Affiliation
AstraZeneca
Official's Role
Study Director
Facility Information:
Facility Name
Almirall Investigational Sites#6
City
Berlin
ZIP/Postal Code
10117
Country
Germany
Facility Name
Almirall Investigational Sites#4
City
Berlin
ZIP/Postal Code
14050
Country
Germany
Facility Name
Almirall Investigational Sites#1
City
Berlin
ZIP/Postal Code
14057
Country
Germany
Facility Name
Almirall Investigational Sites#3
City
Frankfurt
ZIP/Postal Code
60596
Country
Germany
Facility Name
Almirall Investigational Sites#2
City
Grosshansdorf
ZIP/Postal Code
22927
Country
Germany
Facility Name
Almirall Investigational Sites#8
City
Hamburg
ZIP/Postal Code
20249
Country
Germany
Facility Name
Almirall Investigational Sites#5
City
Wiesbaden
ZIP/Postal Code
65187
Country
Germany
Facility Name
Almirall Investigational Sites#2
City
London
ZIP/Postal Code
W1G 8HT
Country
United Kingdom
Facility Name
Almirall Investigational Sites#1
City
Manchester
ZIP/Postal Code
M3 9QZ
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
25398689
Citation
Singh D, Pujol H, Ribera A, Seoane B, Massana E, Astbury C, Ruiz S, de Miquel G. A dose-ranging study of the bronchodilator effects of abediterol (LAS100977), a long-acting beta2-adrenergic agonist, in asthma; a Phase II, randomized study. BMC Pulm Med. 2014 Nov 14;14:176. doi: 10.1186/1471-2466-14-176.
Results Reference
derived
Links:
URL
http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3968&filename=Synopsis-M-100977-202-Final.pdf
Description
Synopsis-M-100977-202
Learn more about this trial
Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.
We'll reach out to this number within 24 hrs